论文部分内容阅读
目的检测PDGF-BB及其受体PDGFR-β在NSCLC中的表达,探讨其表达与NSCLC淋巴管生成及淋巴道转移的关系。方法采用免疫组化SP法检测PDGF-BB及其受体PDGFR-β在113例NSCLC癌组织中的表达水平,分析它们的表达与临床病理参数之间的关系;应用D2-40进行淋巴管染色,计数NSCLC中微淋巴管密度(LMVD);分析PDGF-BB及其受体与微淋巴管密度之间的关系,探讨其在NSCLC淋巴管生成及淋巴道转移中的作用。结果 PDGF-BB主要表达在NSCLC癌细胞的胞膜和胞浆中,其阳性表达率为63.7%(72/113);PDGFR-β主要表达在NSCLC癌巢周围的间质细胞的细胞质中,阳性表达率为61.0%(69/113);PDGF-BB在NSCLC癌细胞中的表达与间质中PDGFR-β的表达明显相关。PDGF-BB、PDGFR-β表达水平与患者的年龄、肿瘤大小、组织类型、分化程度均无关,而与TNM分期、淋巴结转移有关。PDGF-BB阳性表达组其LMVD显著高于阴性表达组(16.5817±5.4556对11.4689±5.5679,P<0.05);PDGFR-β阳性表达组其LMVD显著高于阴性表达组(15.7937±5.6383对11.6917±6.3862,P<0.05)。结论 PDGF-BB及其受体PDGFR-β在NSCLC上的阳性表达可以促进肿瘤淋巴管的生成及淋巴转移,针对这些信号通路的抑制剂的研发将为抑制肿瘤淋巴转移带来新的治疗前景。
Objective To detect the expression of PDGF-BB and its receptor PDGFR-β in NSCLC, and to explore its relationship with lymphangiogenesis and lymph node metastasis in NSCLC. Methods The expression of PDGF-BB and its receptor PDGFR-β in 113 NSCLC tissues was detected by immunohistochemical SP method. The relationship between the expression of PDGF-BB and clinicopathological parameters was analyzed. Lymph tube staining (LMVD) in NSCLC. The relationship between PDGF-BB and its receptor and lymphatic vessel density was analyzed to explore its role in lymphangiogenesis and lymphatic metastasis in NSCLC. Results The positive expression rate of PDGF-BB in the membrane and cytoplasm of NSCLC cancer cells was 63.7% (72/113). PDGFR-β was mainly expressed in the cytoplasm of interstitial cells around NSCLC nests The expression rate of PDGF-BB was 61.0% (69/113). The expression of PDGF-BB in NSCLC cancer cells was significantly correlated with the expression of PDGFR-β in the stroma. The expression of PDGF-BB and PDGFR-βwas not related with the age, tumor size, histological type and differentiation degree of patients, but related to TNM staging and lymph node metastasis. The positive rate of LMVD in PDGF-BB positive group was significantly higher than that in negative group (16.5817 ± 5.4556 vs 11.4689 ± 5.5679, P <0.05). The positive rate of LMVD in PDGFR-β positive group was significantly higher than that in negative group (15.7937 ± 5.6383 vs 11.6917 ± 6.3862 , P <0.05). Conclusion The positive expression of PDGF-BB and its receptor PDGFR-β in NSCLC can promote lymphangiogenesis and lymphatic metastasis. The development of inhibitors of these signaling pathways will bring new therapeutic prospects for the inhibition of lymphatic metastasis.